Knockdown of CUEDC1 restrains the growth and migration of hepatocellular carcinoma cells through affecting the TβRI/Smad signaling pathway

Hepatocellular carcinoma (HCC), as one usual tumor, and owns the significant mortality rates. The involvement of the coupling of ubiquitin conjugation to endoplasmic reticulum degradation (CUE) domain containing 1 (CUEDC1) in cancer progression, either facilitating or inhibiting, has been documented in various cancers. Nevertheless, the regulatory role of CUEDC1 in HCC progression holds unclear. This work aims to elucidate the impact of CUEDC1 on HCC progression. Analysis using the Gene Expression Profiling Interactive Analysis (GEPIA) online database revealed elevated expression of CUEDC1 in liver hepatocellular carcinoma (LIHC) tissues. Subsequently, in HCC cell lines, the elevated CUEDC1 protein expression was confirmed. Silencing CUEDC1 was found to restrain tumor growth in HCC, alongside attenuating cell migration and invasion. Notably, knockdown of CUEDC1 was determined to activate the transforming growth factor-β receptor I (TβRI)/Smad signaling pathway. In conclusion, this study demonstrates that CUEDC1 knockdown restrained the growth and migration of HCC cells under affecting the TβRI/Smad signaling pathway. These findings suggest CUEDC1 could be a helpful target for HCC improvement.

CUEDC1; Migration; Hepatocellular carcinoma; The TβRI/Smad signaling pathway

[1] Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annual Review of Medicine. 2016; 67: 103–117.

[2] Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021; 7: 6.

[3] Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Digestive Diseases. 2009; 27: 80–92.

[4] Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017; 389: 56–66.

[5] Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. BioScience Trends. 2021; 15: 155–160.

[6] Cui Y, Song Y, Yan S, Cao M, Huang J, Jia D, et al. CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer. Aging. 2020; 12: 20047–20068.

[7] Lopes R, Korkmaz G, Revilla SA, van Vliet R, Nagel R, Custers L, et al. CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells. Cancer Letters. 2018; 436: 87–95.

[8] Zhuang WC, Wu QY, Meng FJ, Xu KL. Construction of a lentiviral vector carrying CUEDC1 gene and its effect on the proliferation and colony-formating ability of MOLT-4 Cells. Journal of Experimental Hematology. 2018; 26: 1257–1262. (In Chinese)

[9] Valastyan S, Weinberg R. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147: 275–292.

[10] Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of Hematology and Oncology. 2022; 15: 129.

[11] Zhou C, Liu C, Liu W, Chen W, Yin Y, Li C, et al. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics. 2020; 10: 4627–4643.

[12] Jiang H, Cao H, Ma N, Bao W, Wang J, Chen T, et al. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proceedings of the National Academy of Sciences. 2020; 117: 4770–4780.

[13] Liu D, Zhang T, Chen X, Zhang B, Wang Y, Xie M, et al. ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY. Cell Death & Disease. 2021; 12: 1113.

[14] Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Molecular Cancer. 2022; 21: 104.

[15] Bi J, Zheng J, Li Q, Bao S, Yu X, Xu P, et al. MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-β/Smad pathway in hepatocellular carcinoma. The International Journal of Biochemistry & Cell Biology. 2019; 106: 107–116.

[16] Wan Z, Ma Y, Jiang T, Lin Y, Shi Y, Tan Y, et al. Six2 is negatively correlated with prognosis and facilitates epithelial-mesenchymal transition via TGF-β/Smad signal pathway in hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International. 2019; 18: 525–531.

[17] Gao Z, Zhong M, Ye Z, Wu Z, Xiong Y, Ma J, et al. PAK3 promotes the metastasis of hepatocellular carcinoma by regulating EMT process. Journal of Cancer. 2022; 13: 153–161.